.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Cipla
US Department of Justice
Covington
Queensland Health
Julphar
Novartis
Accenture
Federal Trade Commission
Colorcon

Generated: November 21, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 202179

« Back to Dashboard
NDA 202179 describes PREDNISOLONE SODIUM PHOSPHATE, which is a drug marketed by Vintage, Pharm Assoc, Vintage Pharms, Watson Labs, Alcon Pharms Ltd, Amneal Pharms, Medicis Pharms, Akorn, Edenbridge Pharms, Bausch And Lomb, Sola Barnes Hind, Mylan Pharms Inc, We Pharms, Nesher Pharms, Hi Tech Pharma, Chartwell Rx, Wockhardt, and Mission Pharma, and is included in twenty-eight NDAs. It is available from twenty suppliers. Additional details are available on the PREDNISOLONE SODIUM PHOSPHATE profile page.

The generic ingredient in PREDNISOLONE SODIUM PHOSPHATE is prednisolone sodium phosphate. There are eighty-six drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the prednisolone sodium phosphate profile page.

Summary for 202179

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Hormonal Agents, Stimulant/Replacement/Modifying (Adrenal)
Inflammatory Bowel Disease Agents
Ophthalmic Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 202179

Suppliers and Packaging for NDA: 202179

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
PREDNISOLONE SODIUM PHOSPHATE
prednisolone sodium phosphate
TABLET, ORALLY DISINTEGRATING;ORAL 202179 ANDA Mylan Pharmaceuticals Inc. 0378-4710 0378-4710-22 48 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE, PLASTIC (0378-4710-22)
PREDNISOLONE SODIUM PHOSPHATE
prednisolone sodium phosphate
TABLET, ORALLY DISINTEGRATING;ORAL 202179 ANDA Mylan Pharmaceuticals Inc. 0378-4715 0378-4715-22 48 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE, PLASTIC (0378-4715-22)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, ORALLY DISINTEGRATING;ORALStrengthEQ 10MG BASE
Approval Date:Apr 10, 2013TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, ORALLY DISINTEGRATING;ORALStrengthEQ 15MG BASE
Approval Date:Apr 10, 2013TE:ABRLD:No

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET, ORALLY DISINTEGRATING;ORALStrengthEQ 30MG BASE
Approval Date:Apr 10, 2013TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Cipla
Chubb
Moodys
McKesson
Express Scripts
Argus Health
Deloitte
Healthtrust
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot